Jacob Haaber

Odense University Hospital — Denmark

Medicine · Health Sciences

9h-index468citations33works0.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(17), Chronic Lymphocytic Leukemia Research(11), Multiple Myeloma Research and Treatments(9), Bone health and treatments(6), Lung Cancer Treatments and Mutations(4)

Publications33 total

Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)
Transplantation and Cellular Therapy·2026
Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies
Blood Neoplasia·2025· 1 citedOpen Access
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial
HemaSphere·2025· 2 citedOpen Access
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell Lymphoma
2024Open Access
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Leukemia·2024Open Access
PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
HemaSphere·2023Open Access
PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
HemaSphere·2022Open Access
Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing
Leukemia Research Reports·2022· 1 citedOpen Access
Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4
Scientific Reports·2021· 9 citedOpen Access
Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
Leukemia Research Reports·2021· 3 citedOpen Access
10x Cell Ranger output, 8 samples
Figshare·2021Open Access
10x Cell Ranger output, 8 samples
Figshare·2021Open Access
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
HemaSphere·2020· 34 citedOpen Access
Erratum to “Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma” [Experimental Hematology 84 (2020) 7–18]
Experimental Hematology·2020· 1 citedOpen Access
Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma
Experimental Hematology·2020· 7 citedOpen Access
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Leukemia·2020· 64 citedOpen Access
EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH‐RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME
Hematological Oncology·2019
PB2062 ESTABLISHMENT OF A KNOCKDOWN MODEL FOR UNRAVELLING THE PATHOGENESIS OF MANTLE CELL LYMPHOMA
HemaSphere·2019Open Access
Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma
Leukemia Research·2019
Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines
British Journal of Haematology·2018· 62 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Niels Abildgaard(18), Marcus Høy Hansen(11), Oriane Cédile(11), Charlotte Guldborg Nyvold(10), Simone Valentin Hansen(9), Michael Møller(7), Martin Hutchings(6), Pär Josefsson(5), Gitte Kerndrup(5), Lene Meldgaard Knudsen(4), Ingrid Glimelius(4), Mats Jerkeman(4), Maria Lyng(4), Mia Koldby Blum(4), Peter de Nully Brown(3), Marianne Lodahl(3), Mads Thomassen(3), Thomas Rasmussen(3), Arne Kolstad(3), Kristina Sonnevi(3)